Skip to content

"Clinical application study of the domestic endoscopic robotic system in urology" ——The third topic in the project "Clinical application study of the domestic endoscopic robotic system"

"Clinical application study of the domestic endoscopic robotic system in urology" ——The third topic in the project "Clinical application study of the domestic endoscopic robotic system"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400081949
Enrollment
Unknown
Registered
2024-03-18
Start date
2024-03-21
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign and malignant lesions of urinary system

Interventions

Trial group:Urological surgery using domestic endoscopic surgery robot system including partial nephrectomy, radical prostatectomy, upper urinary tract reconstruction surgery, adrenalectomy and radica

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1)Patients who need partial nephrectomy ( TNM stage : T1, R.E.N.A.L score = 10 ), radical prostatectomy ( TNM stage : T1-3 ), upper urinary tract repair surgery, adrenal tumor resection, and radical resection of bladder cancer ( TNM stage : T1-2 ). (2)Age 18-75 years old, regardless of gender. (3)Patients who agreed to sign the informed consent and could follow the doctor 's advice and regular follow-up.

Exclusion criteria

Exclusion criteria: ( 1 ) Patients with severe heart, lung, brain, liver, kidney disease, can not tolerate surgery or anesthesia ; ( 2 ) Patients can not tolerate pneumoperitoneum ; ( 3 ) Patients with severe coagulation dysfunction ( activated partial thromboplastin time or prothrombin time more than 1.5 times the normal range or platelet count less than 100 × 10 ^ 9 / L ) ; ( 4 ) Patients with active pulmonary tuberculosis ; ( 5 ) Extensive metastasis of the tumor in the abdominal and pelvic cavity ; ( 6 ) Patients with severe uncontrolled disease or acute infection ; ( 7 ) Patients with cardiovascular and cerebrovascular diseases, blood system diseases and diabetes that can not be controlled, can not meet the surgical standards ; ( 8 ) Patients with immune system diseases that cannot be controlled, cannot meet the surgical standards ; ( 9 ) Patients with multiple pelvic and abdominal surgery history, or severe pelvic adhesions ; ( 10 ) Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
success rate of operation ;

Secondary

MeasureTime frame
rate of complications;operation time;hospital stay after operation;

Countries

China

Contacts

Public ContactXuesong Li

Peking University First Hospital

pineneedle@sina.com+86 158 0139 9116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026